InnoCAT

Company Overview

Snapshot

Founded in February 2021 by Yishai Ben David, InnoCAT operates with 1–10 employees. The company has secured funding across two rounds and received a grant from the Israel Innovation Authority in January 2024.

Business overview

InnoCAT develops a wearable electromechanical device for insulin delivery, aiming to simplify diabetes management and enhance patient comfort and safety. The company's proprietary pump architecture integrates user-centric design with efficient electromechanical components to achieve high wearability, usability, and reliability. InnoCAT focuses on manufacturability and cost efficiency to ensure a low cost of goods and scalable production, targeting the Health Tech & Life Sciences sector, specifically in Drug Delivery and Medical Treatment & Therapeutics.

Company Intelligence Q&A

When was InnoCAT founded and by whom?

InnoCAT was founded in February 2021 by Yishai Ben David, who serves as the CEO.

What is InnoCAT's core product?

InnoCAT develops a wearable electromechanical device for insulin delivery, designed to simplify diabetes management and improve patient comfort and safety.

What is InnoCAT's primary business model?

InnoCAT operates with B2C and B2B2C business models, focusing on delivering its insulin pump to patients and through partnerships with medical device manufacturers.

Has InnoCAT received any grants?

In January 2024, InnoCAT secured a grant from the Israel Innovation Authority.

What is the current product stage of InnoCAT?

InnoCAT's product is currently in the Research & Development (R&D) stage, focusing on developing its wearable electromechanical device for insulin delivery.